Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence.
Prediabetes
glucagon-like peptide-1
glucagon-like peptide-1
receptor agonists
impaired fasting glucose
impaired glucose tolerance
liraglutide
Journal
Current diabetes reviews
ISSN: 1875-6417
Titre abrégé: Curr Diabetes Rev
Pays: United Arab Emirates
ID NLM: 101253260
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
09
2019
revised:
20
11
2019
accepted:
12
12
2019
pubmed:
31
12
2019
medline:
12
9
2020
entrez:
31
12
2019
Statut:
ppublish
Résumé
Prediabetes is defined as a state of glucose metabolism between normal glucose tolerance and type 2 diabetes. Continuous β-cell failure and death are the reasons for the evolution from normal glucose tolerance to prediabetes and finally type 2 diabetes. The necessity of new therapeutic approaches in order to prevent or delay the development of type 2 diabetes is obligatory. Liraglutide, a long-acting GLP-1 receptor agonist, has 97% homology for native GLP-1. Identification of the trophic and antiapoptotic properties of liraglutide in preclinical studies, together with evidence of sustained β-cell function longevity during its administration in type 2 diabetes individuals, indicated its earliest possible administration during this disease, or even before its development, so as to postpone or delay its onset. Pubmed and Google databases have been thoroughly searched and relevant studies were selected. This paper explores the current evidence of liraglutide administration both in humans and animal models with prediabetes. Also, it investigates the safety profile of liraglutide treatment and its future role to postpone or delay the evolution of type 2 diabetes. Liralgutide remains a valuable tool in our therapeutic armamentarium for individuals who are overweight or obese and have prediabetes. Future well designed studies will give valuable information that will help clinicians to stratify individuals who will derive the most benefit from this agent, achieving targeted therapeutic strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Prediabetes is defined as a state of glucose metabolism between normal glucose tolerance and type 2 diabetes. Continuous β-cell failure and death are the reasons for the evolution from normal glucose tolerance to prediabetes and finally type 2 diabetes.
INTRODUCTION
BACKGROUND
The necessity of new therapeutic approaches in order to prevent or delay the development of type 2 diabetes is obligatory. Liraglutide, a long-acting GLP-1 receptor agonist, has 97% homology for native GLP-1. Identification of the trophic and antiapoptotic properties of liraglutide in preclinical studies, together with evidence of sustained β-cell function longevity during its administration in type 2 diabetes individuals, indicated its earliest possible administration during this disease, or even before its development, so as to postpone or delay its onset.
METHODS
METHODS
Pubmed and Google databases have been thoroughly searched and relevant studies were selected.
RESULTS
RESULTS
This paper explores the current evidence of liraglutide administration both in humans and animal models with prediabetes. Also, it investigates the safety profile of liraglutide treatment and its future role to postpone or delay the evolution of type 2 diabetes.
CONCLUSION
CONCLUSIONS
Liralgutide remains a valuable tool in our therapeutic armamentarium for individuals who are overweight or obese and have prediabetes. Future well designed studies will give valuable information that will help clinicians to stratify individuals who will derive the most benefit from this agent, achieving targeted therapeutic strategies.
Identifiants
pubmed: 31886752
pii: CDR-EPUB-103310
doi: 10.2174/1573399816666191230113446
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Liraglutide
839I73S42A
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-715Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.